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A fluorescently labelled sialic acid for high
performance intraoperative tumor detection
Xuanjun Wu,a Yunpeng Tian,a Mingzhu Yu,a Bijuan Lin,a Jiahuai Hanb and
Shoufa Han*a
Surgical resection is widely used for tumor treatment, necessitating approaches for the precise locating of
elusive tumor foci. We report the high performance detection of tumors in mice with fluorescein-isothio-
cyanate (FITC) labelled sialic acid (FITC-SA), a fluorescent monosaccharide with low cytoxicity. Analysis of
mice intravenously injected with FITC-SA revealed high target-to-background fluorescence ratios in sub-
cutaneous tumors and liver tumor implants with 0.2–5 mm diameters, which are significantly below the
clinical threshold of minimal residual cancer (∼1 cm clearance). Extracellular FITC-SA is quickly cleared
from circulation whereas the intracellular FITC-SA could be metabolically incorporated into glycoproteins
via a cellular sialylation pathway. Compared with FITC-SA-laden nanoparticles, free FITC-SA is preferen-
tially and quickly taken up by tumors in mice and displays high tumor-to-background signal contrast,
suggesting the potential for fluorescence directed surgical ablation of tumors.
Introduction
Surgical resection remains a major modality for tumor treat-
ment. Incomplete removal of tumor foci, largely dependent on
visual inspection by the surgeon, leads to tumor relapses. As
such, methods that could direct surgeons to disseminated or
evasive tumor foci are valuable for cancer surgery.1 Optical
probes that could selectively accumulate within tumors are
being actively explored for fluorescence guided cancer surgery.
To achieve high tumor-to-background signal ratios, optical
dyes are often conjugated with tumor-targetable carriers such
as folate or monoclonal antibodies, etc.2 The utility of tumor-
targeting optical probes has been validated in clinical trials,
e.g. imaging of epithelial ovarian cancer with FITC-tagged
folate.2c
Sialic acids, a family of natural derivatives of N-acetyl-
neuraminic acid,3 are the common termini of cell surface
glycans involved in host–pathogen interactions and cell–cell
adhesions, etc.4 Overexpression of cell surface sialic acids has
been correlated with the metastatic potential of a number of
tumors, and cell surface sialic acid has been a target for drug
delivery.5 Substrate promiscuity of the sialic acid biosynthetic
pathway has been employed for the biochemical engineering
of cellular sialoproteins with various exogenous N-acyl manno-
samines,6 which are enzymatically condensed with pyruvate to
give unnatural sialic acids for the subsequent sialylation of
glycoproteins.7 The disadvantage associated with the meta-
bolic labelling approach is the lack of cell-type or tissue speci-
ficity, where unnatural sialic acids were found to be present in
different tissues in animals treated with N-acyl mannosamine.8
Analogous to N-acyl mannosamine, sialic acids with C-9 substi-
tutions supplemented in culture medium could also be taken
up by cells and then incorporated into cellular sialoproteins.9
To date, the use of sialic acid derivatives for tumor imaging
in animals has been largely unexplored.10
We herein report the high performance tumor illumination
in mice with 9-fluoresccinylthioureido-9-deoxy-N-acetylneura-
minic acid (FITC-SA), which is preferentially and quickly taken
up by tumors in vivo (Fig. 1). Nanomedicine holds great
promise for targeted drug delivery. For comparison, FITC-SA-
laden boronic acid-functionalized silica nanoparticles were
constructed and assessed for their efficacy to target tumors in
mice.
Results and discussion
Incorporation of FITC-SA into mammalian cells
It was previously shown that sialic acids with bulky substi-
tutions at the C-9 position could be effectively incorporated
into cell surface glycoproteins on B cells.9a In addition, CMP
activated FITC-SA has been shown to be the functional donor
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of sialyltransferases and used to transfer FITC-SA to endogen-
ous glycoproteins in permeabilized Chinese hamster ovary
cells.11 On the basis of these observations, we examined the
feasibility of illuminating tumors in mice by systemic adminis-
tration of FITC-SA.
To probe cell type-dependent uptake of FITC-SA, Raw
264.7 macrophages, human epithelial carcinoma (HeLa),
human hepatocellular carcinoma (QGY-7701), human primary
glioblastoma (U87-MG), H22 hepatocellular carcinoma,
murine microglial cells (BV-2) and human embryonic kidney
293 cells, a normal tissue cell line, were respectively cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with FITC-SA and DiI, which is a plasma membrane specific
dye. The intracellular fluorescence was visualized as a function
of incubation time by confocal fluorescence microscopy. It was
shown that intense FITC signals were clearly present in all cell
lines examined (Fig. 2), suggesting that FITC-SA supplemented
in culture medium could be effectively taken up by a broad
spectrum of tumor cell lines and normal tissue cells. Images
of individual cells at different stages of incubation revealed the
punctate and discrete fluorescence of FITC-SA is mostly con-
fined within the cytosol of BV-2 cells, whereas the cytosolic
FITC-SA in Raw 264.7, QGY-7701, and U87-MG cells largely
relocates to cell membranes upon prolonged incubation, as
indicated by the increased colocalization of the FITC-SA signal
with the DiI fluorescence (Fig. 2).
The tempo-spatial alterations of the intracellular fluo-
rescence patterns shown in Fig. 2 suggest that FITC-SA could
be incorporated into endogenous glycoproteins which are
further sorted to distinct subcellular locations (e.g. cell mem-
brane) in a cell-type dependent manner. Confocal fluorescence
microscopic images of HeLa, U87-MG, and BV-2 cells co-
stained with FITC-SA, Lyso-Tracker Blue DND-22, Mito-Tracker
Deep Red, and Golgi-Tracker Red show the presence of
FITC-SA within the Golgi, whereas no obvious FITC-SA signals
are present in lysosomes and mitochondria (Fig. 3B), which is
consistent with the fact that cytosolic CMP-SA is transported
into the Golgi apparatus for protein sialylation. To further
prove metabolic incorporation of FITC-SA into cellular pro-
teins, HeLa cells pretreated with FITC-SA and DiI were permea-
bilized and fixed with formaldehyde and then incubated in
fresh DMEM for 12 h to remove unbound FITC-SA within cells.
As shown in Fig. 4, no staining of the cell membrane with DiI
was observed in cells treated with formaldehyde, confirming
disruption of the functional cell plasma membrane.
The bright FITC-SA signal remaining in treated cells indicates
covalent incorporation of FITC-SA into cellular proteins
(Fig. 4). Collectively, these results show that FITC-SA is compa-
tible with the cellular sialylation pathway, which enables meta-
bolic labelling of host cells with FITC-SA.
Detection of subcutaneous tumors with FITC-SA
Effectively taken up by different tumor cell lines in vitro,
FITC-SA was further assessed for its capability to accumulate
in subcutaneous tumors in mice. ICR mice were inoculated
subcutaneously with H22 hepatocellular carcinoma cells and
then maintained for 5–10 days to allow the development of
tumor xenografts. FITC-SA was injected via the tail vein into a
cohort of tumor-bearing mice. The mice were sacrificed at
20 min, 1.5 h, 4 h and 10 h following injection. The tumors
and representative organs were dissected and then probed by
ex vivo fluorescence analysis. An intense FITC-SA signal is
observed in tumors within 20 min after administration of
FITC-SA (Fig. 5A), suggesting quick tumoral uptake of FITC-SA
Fig. 1 Schematic diagram of FITC-SA based tumor imaging. FITC-SA
was preferentially taken up into tumors and then incorporated into cel-
lular proteins through an endogenous sialylation pathway.
Fig. 2 Tempo-spatial distribution of FITC-SA within mammalian cells.
Raw 264.7, HeLa, QGY-7701, U87-MG and BV-2 cells were respectively
incubated in DMEM containing FITC-SA (100 μM) for 1–24 h, followed
by staining with DiI (10 μM) for 10 min and then analysis by fluorescence
confocal microscopy to pinpoint the subcellular locations of FITC-SA.
The cell membrane was stained by DiI. Overlay of FITC-SA (green signal)
with DiI (red signal) reveals colocalization, as indicated by the yellow
areas. Bars: 10 μm.
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from the bloodstream. The fluorescence in the brain, also
observed 20 min after injection, quickly diminished to
background levels 4 h postinjection, meanwhile no obvious
accumulation of FITC-SA was identified in other healthy
organs examined (Fig. 5A). The tumor-to-organ fluorescence
ratios remained high up to 10 h postinjection (Fig. 5B).
To probe the location of FITC-SA within tumors, cells were
released from the excised tumors and organs by digestion
with trypsin, and then visualized by confocal fluorescence
microscopy. Fig. 6 revealed the intracellular fluorescence of
FITC-SA within cells from tumors, and brain etc., confirming
transportation of FITC-SA from the bloodstream into tumor
cells. Taken together, the fast and preferential uptake of
FITC-SA by tumors in vivo and the resultant high tumor-to-
background signal ratios suggests the utility of FITC-SA for low
background intraoperative tumor detection.
Illumination of liver tumor implants in mice with FITC-SA
Hepatocellular carcinoma, the predominant form of liver
cancer, is a common and lethal malignancy claiming more
than 600 000 lives each year.12 Cytoreduction remains one of
the major approaches for liver cancer therapy. Residual tumor
foci due to incomplete surgical removal often lead to tumor
relapses. Encouraged by the selective imaging of subcutaneous
tumors with FITC-SA, we further evaluate the efficacy of
FITC-SA to illuminate liver tumor foci in mice. ICR mice with
Fig. 3 Subcellular locations of FITC-SA. HeLa, U87-MG and BV-2 cells
were respectively incubated in DMEM containing FITC-SA (100 μM) for
4 h, stained with Golgi-Tracker Red (333 μg ml−1) in DMEM at 4 °C for
30 min, and then incubated in DMEM with LysoTracker Blue DND-22
(1 μM) and Mito-Tracker Deep Red (500 nM) for 30 min at 37 °C with 5%
CO2. The cells were analyzed by fluorescence confocal microscopy to
pinpoint the subcellular locations of FITC-SA (A). Overlay of FITC-SA
signals with those of Mito-Deep Red and Golgi-Tracker Red reveals
partial colocalization of FITC-SA with Golgi-Tracker Red, which is indi-
cated by the yellow areas. Bars: 10 μm.
Fig. 4 Metabolic incorporation of FITC-SA into cellular proteins. HeLa
cells prestained with FITC-SA (100 μM) were digested by trypsin and
then cultured in DMEM for 12 h. The cells were treated with or without
formaldehyde (4%) for 15 min in PBS, incubated in fresh DMEM for 12 h
to allow the clearance of free FITC-SA, and stained with DiI (10 μM) for
10 min and then imaged by fluorescence confocal microscopy. The cell
membrane stained with DiI was shown in red and the intracellular
FITC-SA was shown in green.
Fig. 5 High-efficiency illumination of subcutaneous tumors with
FITC-SA. ICR mice bearing subcutaneous tumors were intravenously
injected with FITC-SA (50 mg kg−1) or PBS (100 μl) via the tail vein and
then sacrificed 20 min, 1.5 h, 4 h and 10 h post-injection. (A) Ex vivo flu-
orescence images of the dissected tumors and representative organs.
(B) The bar graph shows the tissue distributions of the FITC-SA fluor-
escence. The organs were shown in the following sequence: liver (1),
tumor (2), lung (3), heart (4), kidney (5), spleen (6), and brain (7).
Fig. 6 Cellular uptake of intravenously injected FITC-SA in mice. Mice
bearing subcutaneous tumors were intravenously injected with FITC-SA
(50 mg kg−1) and then sacrificed 2.5 h postinjection. The tumors and
representative organs were dissected, minced and digested with trypsin-
EDTA solution (0.125%) for 30 min. The liberated cells were visualized by
confocal fluorescence microscopy.
Paper Biomaterials Science

































tumor implants of H22 hepatocellular carcinoma in the liver
were intravenously administered with FITC-SA. The liver and
selected organs were excised 17 h after injection. Ex vivo fluo-
rescence analysis revealed intensive fluorescence from tumor
foci in the liver and low levels of signals in neighbouring liver
tissue and other healthy organs (Fig. 7). The tumor implants
with diameters of 0.2–5 mm could be clearly discerned with
FITC-SA. The resolution is significantly below the minimal
residual cancer (<1 cm) limit pursued by surgeons.13 The high
tumor-to-background fluorescence contrasts and the detection
of sub-millimeter tumors further corroborate the potential of
FITC-SA for fluorescence guided tumor surgery.
Tissue or cell-specific delivery of functional sugars is of sig-
nificant interest in biomedical studies of cellular glycosylation.
In contrast with N-acyl mannosamines widely used for the
metabolic remodelling of sialoconjugates, sialic acid deriva-
tives, albeit taken up by cells in vitro, are less well explored for
animal studies. N-Acetyl-3-[18F]fluoroneuraminic acid and
N-acetyl-2-deoxy-2,3-di-[18F]fluoroneuraminic acid were found
to show limited tumor accumulation in mice as determined by
positron emission tomography.10 Recently, folate-decorated
liposomes were employed for selective and enhanced delivery
of azido-sialic acid into folate receptor-overexpressing cells.14
The unexpected high performance detection of tumors with
FITC-SA in mouse models is likely due to a combination of a
distinct tumor-targeting property of FITC-SA, a sialic acid
derivative with C-9 substitution, relative to [18F]-substituted
sialic acids,10 and high sensitivity of fluorometry over positron
emission tomography. It is reported that hours are required
for efficient cell surface glycan labeling with acetylated N-acyl-
mannosamine, the metabolic precursor of sialic acids.7 In the
case of intraoperative tumor detection, FITC-SA inside cells, or
later metabolically displayed on the cell surface, effectively
contributes to detectable intra-tumoral signals, which might
account for the observed fluorescecne within tumors at 20 min
postinjection.
FITC-SA is compatible for intraoperative tumor imaging
owing to exposure of cancerous tissues, which circumvents the
limited tissue penetration of fluorescein fluorescence. In
addition, fluorescein, the optical reporter of FITC-SA, provides
bright and green emission bioorthogonally distinct from the
autofluorescence located in the visible-to-red region. Although
the molecular or physiological factors underlying the selective
tumor uptake of FITC-SA in vivo remain elusive at this stage,
the high tendency of FITC-SA to accumulate in tumors
suggests the use of sialic acids with appropriate modifications
for low background tumor detection.
Construction and characterization of FITC-SA loaded
mesoporous silica nanoparticles
Nanomedicine holds enormous potential for targeted drug
delivery. Nanoscaled systems are actively being explored for
tumor targeting due to the enhanced permeability and reten-
tion (EPR) effect.15 Akin to hydrazone and orthoesters widely
explored for lysosomal pH promoted drug release,16 boronic
acid–cis diol esters are prone to acidic pH mediated hydrolysis.
To compare the performance of nanovector mediated tumor
imaging, FITC-SA was loaded into boronic acid-displaying
mesoporous silica nanoparticles (MSN) and then applied for
tumor imaging.
MSN was capped with [3-(O-boronobenzyl)aminopropyl]-
triethoxysilane (BA-APTS) in anhydrous DMF under reflux for
24 h to give BA@M which was further modified with poly-
(ethylene glycol) to give BA@M-P (Scheme 1). BA@M and
BA@M-P were respectively incubated with excess FITC-SA in
DMF and then harvested by centrifugation. Analysis shows
that the hydrodynamic diameters of sugar-laden MSN
remained largely unaffected while the surface potentials
slightly decreased upon complexation with FITC-SA (Fig. 8),
indicating anionic FITC-SA was largely encapsulated into the
Fig. 7 High performance illumination of liver tumors with FITC-SA. ICR
mice with liver tumor implants were intravenously injected with FITC-SA
(50 mg kg−1) or PBS (100 μl) via the tail vein and then sacrificed 17 h
postinjection. (A) Ex vivo fluorescence images of the excised livers and
selected organs; (B) tumor foci highlighted in the square were enlarged
for clarity; (C) the bar graph shows the fluorescence intensity of FITC-SA
in tumor foci vs. surrounding liver tissue and other organs. Bar: 1 cm.
Scheme 1 Boronic acid-displaying MSN for intracellular delivery of
FITC-SA. Sugar-laden MSN undergoes acidic pH promoted hydrolysis of
the boronate-diol ester.
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pores of silica particles. To assess the pH mediated release of
MSN-captured FITC-SA, FITC-SA@BA@M and FITC-SA@
BA@M-P were separately incubated in sodium phosphate
buffers of pH 4.5 or pH 7.5. At fixed time intervals, portions of
the mixtures were centrifuged, and the amounts of FITC-SA
remaining in the silica particles were quantified by UV-vis
spectrometry. It was shown that levels of FITC-SA within MSN
incubated at acidic pH decreased dramatically relative to those
at pH 7.5 (Fig. 9), indicating the applicability of acidic pH
mediated hydrolysis of boronic acid complexed FITC-SA.
As the major acidic cellular vesicles, lysosomes are fre-
quently explored to promote therapeutic release from endo-
cytosed nanocarriers. As MSNs are often internalized into
lysosomes,17 HeLa cells were cultured with FITC-SA-laden MSN
in DMEM and then stained with DiI and LysoTracker Blue.
Strong fluorescence of FITC-SA was identified inside treated
cells. The partial colocalization of FITC-SA with LysoTracker
Blue, which selectively stains lysosomes, proves sugar-loaded
MSN could be internalized into lysosomes. The rise of the
extralysosomal FITC-SA signal within cells upon further incu-
bation indicates the release of FITC-SA from the nanocarriers
(Fig. 10).
Tumor detection with FITC-SA-laden MSN
To evaluate the in vivo performance of the sugar-laden MSN,
FITC-SA@BA@M and FITC-SA@BA@M-P were respectively
injected via the tail vein into ICR mice harbouring sub-
cutaneous tumors. The mice were sacrificed 10 and 22 h post-
injection and the biodistribution of the nanoprobes was
assessed by measuring fluorescence emission in the dissected
organs and tumors. As shown in Fig. 11, tumor-associated
fluorescence was negligible at 10 h and became evident by
22 h postinjection in mice treated with FITC-SA@BA@M,
whereas no obvious fluorescence could be discerned in tumors
in mice treated with FITC-SA@BA@M-P. Hepatocytes efficien-
tly capture nanoscaled materials,18 which likely contributes to
the bright fluorescence observed in the liver (Fig. 11). Com-
pared with FITC-SA, sugar-laden MSN displays slow kinetics of
accumulation into tumors and low tumor-to-normal organ
fluorescence ratios (Fig. 11).
Cytotoxicity of FITC-MSN and FITC-SA-loaded MSN
The cytotoxicity of FITC-SA, FITC-SA@BA@M and FITC-SA@
BA@M-P was evaluated in HeLa cells by the Trypan Blue exclu-
sion test. No detrimental effects on cell viability were observed
at doses up to 1 mM for FITC-SA or 100 μg ml−1 for FITC-SA-
loaded MSN after incubation for 24 h (Fig. 12), suggesting that
FITC-SA and boronic acid-displaying MSN are of low cell
toxicity.
Fig. 8 Dynamic light scattering (A) and zeta potential analysis (B) of
sugar-laden MSN as compared to sugar-free MSN.
Fig. 9 pH dependent release of FITC-SA from sugar-loaded MSN.
FITC-SA@BA@M (A) (10 mg ml−1) or FITC-SA@BA@M-P (B) (10 mg ml−1)
incubated at Na2HPO4–H3PO4 buffer (100 mM, pH 4.5 or 7.5) for 0–4 h.
A portion of the mixture (100 μl) was centrifuged. The supernatant free
of nanoparticles was removed and the pellets were resuspended in
Na2HPO4–H3PO4 buffer (100 mM, pH 7.5) and then analyzed by UV-vis
absorbance spectroscopy.
Fig. 10 Uptake of FITC-SA-laden MSN into HeLa cells. HeLa cells were
cultured for 24 h in DMEM supplemented with FITC-SA@BA@M (50 μg
ml−1) (A) or FITC-SA@BA@M-P (50 μg ml−1) (B) for 4 and 24 h. The cells
were stained with DiI (10 μM) in DMEM for 10 min, incubated with Lyso-
Tracker Blue DND-22 (1 μM) for 30 min, and then analyzed by confocal
fluorescence microscopy. Overlay of green fluorescein signals and red
DiI signals reveals colocalization where yellow areas were presented.
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We demonstrate the use of FITC-SA for high performance illu-
mination of subcutaneous tumors and liver tumors in mice via
quick and selective tumor uptake of systemically administered
FITC-SA. Tissue-specific incorporation of functional sugars is
valuable for a number of applications. For instance, the avidity
of tumors for glucose over normal tissues underlies the use of
[18F]-2-fluoro-2-deoxyglucose (18FDG) for tumor prognosis.19 In
contrast with 18FDG with a half life of 109 min, FITC-SA is
also a simple and structurally defined monosaccharide with
superior chemical and physical stability under physiological
conditions. The demonstrated advantageous in vivo tumor-
targeting properties of FITC-SA over sugar-laden silica nano-
particles, including effective resolution of mm-level tumor
foci, high tumor-to-background signal ratios and fast imaging
kinetics, not only validate its clinical potential for fluorescence
guided intraoperative tumor detection, but also suggest the
promising use of sialic acids with appropriate modifications
for a number of biomedical studies, such as manipulating
tumor surface sialylation in living animals.
Experimental
Material and methods
LysoTracker Blue DND-22 and MitoTracker Deep Red were
purchased from Invitrogen. Golgi-Tracker Red and DiI (1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate)
were purchased from Beyotime. Fluorescein isothiocynate
isomer I (FITC), Dulbecco’s Modified Eagle Medium (DMEM)
and fetal bovine serum (FBS) were purchased from Sigma-
Aldrich. FBS was inactivated by heating at 60 °C for 30 min.
FITC-SA was synthesized according to a published pro-
cedure.11a All other chemicals were used as received from Alfa
Aesar. QGY-7701 cells, U-87 MG cells, HeLa cells, Raw 264.7
cells and BV-2 cells were obtained from American Type Culture
Collection and grown at 37 °C under 5% CO2 in DMEM.
The fluorescence spectra and UV-vis absorbance spectra
were recorded on a spectrofluorimeter (Spectramax M5, Mole-
cular Device). Dynamic light scattering and Zeta potential ana-
lysis of the nanoparticles were performed on a Zetasizer Nano
ZS (ZEN3500, Malvern). Confocal microscopic images were
obtained on a Leica SP5 using the following filters:
λex@543 nm and λem@560–625 nm for DiI; λex@543 nm
and λem@580–650 nm for Golgi-Tracker Red; λex@633 nm and
λem@700–790 nm for MitoTracker Deep Red; λex@488 nm and
λem@500–530 nm for FITC-SA. Fluorescence images were
merged by Photoshop CS 6.0. Graphs were processed with
Origin 8.5 software. Fluorescence quantification of the organs
of mice were performed on a Carestream FX PRO in vivo
imaging system using an excitation filter of 470 nm and an
emission filter of 535 nm. Data were analyzed with Carestream
MI SE. ICR mice were purchased from Xiamen University Labo-
ratory Animal Center. H22 hepatocellular carcinoma cells
were collected from the peritoneal cavity of tumor-bearing
mice and then used for innoculation of tumors in ICR mice.
All animal experiments were performed in accordance with the
guidelines of Xiamen University’s Animal Care and Use
Committee.
Preparation of BA@M and BA@M-P
3-Aminopropyltrimethoxysilane (APTS, 6 ml) was incubated in
dichloromethane (20 ml) containing 2-bromomethylbenzyl-
boronic acid (3 g) for 1 h. The resulting precipitate (BA-ABPS)
was filtered and the organic layer was concentrated by evapor-
ation to afford BA-APTS. To distilled water (480 ml) was added
N-cetyltrimethylammonium bromide (1.0 g), aqueous sodium
Fig. 12 In vitro cytotoxicity of FITC-SA, FITC-SA@BA@M or FITC-SA@
BA@M-P. HeLa cells were respectively cultured in DMEM medium con-
taining various levels of FITC-SA (A, 0–1 mM), FITC-SA@BA@M (B, in
black, 0–100 mg ml−1) or FITC-SA@BA@M-P (B, in red, 0–100 mg ml−1)
for 24 h. The cell number and cell viability were determined by the
trypan blue exclusion assay.
Fig. 11 Detection of subcutaneous tumors in mice with FITC-SA@
BA@M or FITC-SA@BA@M-P. ICR mice with H22 subcutaneous tumors
were respectively injected with FITC-SA@BA@M (10 mg kg−1), FITC-
SA@BA@M-P (10 mg kg−1) or PBS (100 μl) via the tail vein. The mice were
sacrificed 10 h and 22 h postinjection. Ex vivo fluorescence images of
the subcutaneous tumors and representative organs from mice treated
with FITC-SA@BA@M (A) or FITC-SA@BA@M-P (B). The bar graph shows
FITC-SA fluorescence intensity in tumor vs. healthy organs, shown in the
following sequence: liver (1), tumor (2), lung (3) heart (4), kidney (5) and
spleen (6) and brain (7).
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hydroxide solution (2.0 M, 3.6 ml) and tetraethoxysilane
(4.8 ml). The mixture was vigorously stirred at 80 °C for 1 h
and then centrifuged at 10 000 rpm for 5 min. The pellet was
washed with distilled water and methanol, and then refluxed
in methanol (180 ml) containing hydrochloric acid (12.1 M,
10 ml) for 24 h. The mixture was centrifuged and the pellet
was subjected to repeated suspension in methanol by soni-
cation and centrifugation to afford MSN. BA-APTS (600 mg)
was dissolved in anhydrous DMF (4 ml) and then added drop-
wise into anhydrous DMF (50 ml) containing MSM (600 mg).
The mixture was stirred for 20 h at 80 °C and then centrifuged
at 10 000 rpm for 10 min. The pellet was washed with metha-
nol to afford BA@M. mPEG-SPA (300 mg) was added into anhy-
drous DMF (25 ml) containing BA@M (300 mg) and
triethylamine (300 μl). The mixture was sonicated for l h and
then centrifuged to give BA@M-P which was further washed
with DMF and then stored in DMSO before use.
Complexation of FITC-SA with B@M and B@M-P
B@M (150 mg) and B@M-P (150 mg) were respectively added
to methanol (25 ml) containing FITC-SA (50 mg). The mixtures
were refluxed for 30 min, maintained at rt overnight with
gentle stirring and then centrifuged to afford FITC-SA@B@M
and FITC-SA@B@M-P. FITC-SA@B@M and FITC-SA@B@M-P
were resuspended in DMSO (20 mg ml−1) for subsequent
analysis.
Characterization of FITC-SA laden MSN
B@M, B@M-P, FITC-SA@BA@M and FITC-SA@B@M-P were
respectively spiked in distilled water to a final concentration of
200 μg ml−1. The mixtures were sonicated and then analyzed
by a Zetasizer Nano ZS (ZEN3500, Malvern) to obtain their
hydrodynamic sizes and Zeta potentials.
pH dependent release of FITC-SA from sugar-laden MSN
FITC-SA@BA@M (10 mg) or FITC-SA@BA@M-P (10 mg) was
added to Na2HPO4–H3PO4 buffer (100 mM, 1 ml, pH 4.5 or
7.5). The mixtures were sonicated and then maintained at rt
with stirring. At fixed time points (0, 1, 2, 4 h), 100 μl of the
mixture was aliquoted and centrifuged at 10 000 rpm for
10 min. The supernatant free of nanoparticles was removed
and the pellets were resuspended in Na2HPO4–H3PO4 buffer
(1 ml, 100 mM, pH 7.5) and then analyzed for UV-vis
absorbance.
Cellular uptake of FITC-SA and FITC-SA laden MSN
Raw 264.7, QGY-7701, U87-MG, HeLa and BV-2 cells were
respectively seeded on 35 mm glass-bottom dishes (NEST) and
incubated for 24 h in DMEM supplemented with 10% FBS.
The cells were spiked with one of the following species:
FITC-SA (100 μM), FITC-SA@BA@M (50 μg ml−1) or FITC-SA@
BA@M-P (50 μg ml−1) for 1–24 h. The cells were washed with
PBS (1 ml), and then stained with DiI (10 μM) for 10 min. The
cells incubated with FITC-SA laden MSN were stained with
LysoTracker Blue DND-22 (1 μM) for 30 min and then analyzed
by confocal fluorescence microscopy to determine the intra-
cellular location of FITC-SA and DiI.
Determination of subcellualr location of FITC-SA
HeLa, U87-MG and BV-2 cells were respectively cultured in
DMEM for 24 h and then treated with FITC-SA (100 μM) for
4 h. The cells were then stained with Golgi-Tracker Red (333 μg
ml−1) at 4 °C for 30 min according to the manufacturer’s proto-
col, and cultured with LysoTracker Blue DND-22 (1 μM) and
MitoTracker Deep Red (500 nM) for 30 min in DMEM at 37 °C
with 5% CO2. The cells were analyzed by fluorescence confocal
microscopy to determine the intracellular locations of FITC-SA
and the cell markers.
Fixation of cells
HeLa cells were stained with FITC-SA (100 μM) for 4 h and then
digested by trypsin. The cells were harvested and then cultured
for 12 h in DMEM. The cells were stained with DiI (10 μM) in
DMEM for 10 min and treated with or without formaldehyde
(4%) for 15 min in PBS. The treated cells were incubated in
fresh DMEM for 12 h and then imaged by fluorescence confocal
microscopy for DiI and FITC-SA signals.
Cytotoxicity of FITC-SA and FITC-SA laden MSN
HeLa cells were respectively cultured for 24 h in DMEM con-
taining various levels of FITC-SA (0–1 mM), FITC-SA@BA@M
(0–100 μg ml−1) or FITC-SA@BA@M-P (0–100 μg ml−1). The
cell number and cell viability were determined by trypan blue
exclusion.
Imaging of subcutaneous tumors in mice with FITC-SA
ICR mice were xenografted in the flank by subcutaneous injec-
tions of H22 cells (1 × 106). At 5–10 days after the transplan-
tation, FITC-SA (50 mg kg−1) or PBS (100 µl) were respectively
injected intravenously via the tail vein into tumor-bearing
mice. At 20 min, 1.5 h, 4 h or 10 h following injection, the
mice were anesthetized. The tumors and selected organs were
excised, washed with PBS and then subjected to ex vivo analy-
sis for the fluorescence intensity of FITC-SA.
Intracellular distribution of FITC-SA in subcutaneous tumors
ICR mice with subcutaneous tumors were injected intra-
venously via the tail vein with FITC-SA (50 mg kg−1). At 2.5 h
following injection, the mice were anesthetized. The tumors
and selected organs were excised, washed with PBS and then
minced to 3–5 mm with sterile scissors, and then incubated in
Trypsin-EDTA solution (0.125%) for 30 min. The liberated cells
were visualized by confocal fluorescence microscopy.
Imaging of subcutaneous tumors in mice with FITC-SA laden
MSN
FITC-SA@B@M (10 mg kg−1), FITC-SA@B@M-P (10 mg kg−1)
and PBS were respectively intravenously injected into the afore-
mentioned ICR mice bearing subcutaneous tumor implants.
At 10 h and 22 h postinjection, the mice were anesthetized.
The tumors and selected organs were excised, washed with
Paper Biomaterials Science

































PBS and then subjected to ex vivo analysis to determine the
fluorescence intensity of FITC-SA.
Detection of liver tumors in mice with FITC-SA
ICR mice xenografted in the liver with H22 cells were obtained
from the animal center of Xiamen University. At 5–10 days
after transplantation, the mice were injected intravenously via
the tail vein with FITC-SA (50 mg kg−1 in mice) or PBS (100 µl).
After 17 h, the mice were anesthetized. The liver and healthy
organs were excised, washed with PBS and then subjected to
ex vivo analysis to determine the fluorescence intensity of
FITC-SA.
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